Mirum Pharmaceuticals, INC Schedule 13G passive stakes

Janus Henderson Group Ltd. has disclosed beneficial ownership of 5,909,184 shares, representing 9.7% of Mirum Pharmaceuticals, Inc.'s common stock, as of June 30, 2026.

FMR LLC has disclosed beneficial ownership of 6.2% of Mirum Pharmaceuticals Inc.'s common stock as of June 30, 2026.

BlackRock Inc. has disclosed a beneficial ownership of 5.7% in Mirum Pharmaceuticals, Inc. as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Mirum Pharmaceuticals Inc. following an internal realignment.

Eventide Asset Management, along with Finny Kuruvilla and Robin C. John, reported a 4.1% beneficial ownership stake in Mirum Pharmaceuticals, Inc. as of December 31, 2025.

Janus Henderson Group plc has disclosed an increased beneficial ownership of 10.6% in Mirum Pharmaceuticals, Inc. common stock.

Biotechnology Value Fund and its affiliates reported a collective 3.0% passive ownership stake in Mirum Pharmaceuticals, Inc. as of September 30, 2025.

Janus Henderson Group plc has increased its beneficial ownership in Mirum Pharmaceuticals, Inc. to 10.0% of common stock.

Janus Henderson Group plc has increased its beneficial ownership in Mirum Pharmaceuticals, Inc. to 10.6% of common stock, as disclosed in its latest Schedule 13G/A filing.

Investment giant Janus Henderson Group plc has reported a 10.3% beneficial ownership stake in Mirum Pharmaceuticals, Inc., as detailed in its latest Schedule 13G Amendment No. 5 filing with the SEC.

Janus Henderson Group PLC has filed an Amendment No. 4 to its Schedule 13G, disclosing a beneficial ownership of 9.7% in Mirum Pharmaceuticals, Inc. as of March 31, 2025.

Janus Henderson Group PLC and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have disclosed a combined beneficial ownership of 14.3% in Mereo BioPharma Group PLC's American Depositary Shares as of March 31, 2025.

Janus Henderson Group PLC has filed an amended Schedule 13G, revealing a 10.1% beneficial ownership stake in Mirum Pharmaceuticals, Inc. as of April 30, 2025.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a 9.5% beneficial ownership stake in Mirum Pharmaceuticals, Inc. as of December 31, 2024.

Janus Henderson Group plc and its affiliate have reported a combined beneficial ownership of 11.0% in Mereo BioPharma Group plc's American Depositary Shares as of December 31, 2024.

Eventide Asset Management, along with Finny Kuruvilla and Robin C. John, reported a beneficial ownership of 5.43% in Mirum Pharmaceuticals, Inc. as of December 31, 2024.

Eventide Asset Management, LLC, along with Finny Kuruvilla, M.D., Ph.D., and Robin C. John, have filed an amended Schedule 13G disclosing a combined beneficial ownership of 3.46% of Inozyme Pharma, Inc.'s common stock as of December 31, 2024.